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The technical challenges in the development of a quality-controlled registry of percutaneous coronary 
interventions (PCIs) are currently unknown. This article describes the authors ’ experience in the development of 
a regional, quality-controlled PCI registry. In 1996, 16 centers in Michigan were invited to participate in a 
multicenter PCI registry. Nine centers agreed to a pilot data collection and, as of July 2001, eight centers are still 
actively collecting data. An Oracle database was developed by the coordinating center. A common data collection 
form and a standard set of definitions were agreed on during several meetings. Data validity was insured through 
review of each form by a trained nurse, by automatic database diagnostic routines, and by site visits that included 
a review of the catheterization laboratory logs and a review of randomly selected charts. The average number of 
forms requiring query resolution was 33% in 1997 (range 7-76%), and it decreased to 5% in I999 (range 
1.4-10%). The most commonly queried variables were outcomes prior to discharge, lesion category, lesion 
complexity, date of birth, device used, gender, postprocedural percent stenosis, presence of leji main disease, and 
MI date. Invalid dates, identification of the doctor, the presence of duplicate forms, and of duplicate outcomes were 
additional common queries generated by the internal diagnostic routines. In conclusion, the number of queries and 
diagnostic reports generated in the database suggests that the development of a quality-controlled PCI registry 
requires the institution of a careful diagnostic and data quality assessment system. ( J  Interven Cardiol 
2002; 15:387-392) 
Introduction 
The development of multicenter registries to mea- 
sure outcomes is becoming increasing popular as 
health care costs continue to rise and medical practi- 
Supported in part by a grant from the Blue Cross Blue Shield of 
Michigan Foundation, Detroit, Michigan. 
Address for reprints: Mauro Moscucci, M.D., University of Michi- 
gan Medical Center, Taubman 3910. 1500 East Medical Center Dr., 
Ann Arbor, MI 48109-0022. Fax: (313) 936-5626; e-mail 
moscucci@umich.edu 
tioners are being closely scrutinized regarding appro- 
priateness of procedures, resource use, and cost-effec- 
tiveness of care delivered. Health care purchasers and 
payors and governmental health care organizations, 
like the Health Care Financing Administration 
(HCFA), are requiring documentation of outcomes to 
validate that care was delivered effectively and appro- 
priately. 
As a subspecialty of cardiology, interventional car- 
diology continues to advance since 1977 when the first 
percutaneous revascularization was performed. With 
rapid evolution of technology, continued demand, and 
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expanding indications for percutaneous procedures 
comes the need to measure outcomes in community- 
based hospitals and tertiary care centers to insure that 
the high costs associated with these procedures are as- 
sociated with optimal outcomes. 
Outcome measurements have also been used as cat- 
alysts for quality improvement efforts. Some of the 
goals of quality improvement efforts are to insure ap- 
propriateness of procedures, cost-effectiveness, effi- 
cient delivery of care, and optimal resource use. One 
component of the quality improvement process is 
benchmarking, the process of identifying the best 
practice. By benchmarking, individuals and institu- 
tions are able to evaluate their own practices using the 
best practice as the criterion standard. Using this stan- 
dard, individuals and institutions can plan and imple- 
ment strategies to improve practice and outcomes. In 
the field of percutaneous coronary intervention (PCI), 
which is rapidly evolving, few well-established bench- 
marks are available. As a result, multicenter registries 
offer the opportunity to identify the best practices in 
real time on a regional basis, as they evolve. 
The Blue Cross Blue Shield of Michigan Cardio- 
vascular Consortium (BMC2) is a voluntary consor- 
tium of physicians, nurses, and administrators from 
eight hospitals in the state of Michigan who have 
agreed to participate in a multicenter registry of percu- 
taneous coronary interventions (PCIs). The consor- 
tium is designed to extend over a 5-year period and in- 
corporates a quality improvement phase. The purpose 
of the consortium is to develop a continuous quality 
improvement program, to prospectively evaluate ap- 
propriateness of percutaneous procedures, to develop 
and validate risk adjustment models for fatal and non- 
fatal outcomes of PCIs, and to apply these models in 
assessing the quality of care. This article describes the 
structure of data collection, validation procedures, and 
reporting of outcomes. 
Methods 
Participating Hospitals. In the summer of 1996,16 
academic and community hospitals in the Blue Cross 
Blue Shield of Michigan Centers of Excellence were 
asked to voluntarily participate in the registry. Nine 
hospitals agreed (three academic and six community) 
and were represented at the start-up meeting in early 
1997. A 1-month pilot study was conducted in July 
1997 followed by initiation of an ongoing registry on 
December 1, 1997. 
Data Form. A one page (two-sided) data form that 
included demographic and procedural variables, past 
medical history, primary indication for PCI, priority, 
appropriateness, therapies, cardiac anatomy and func- 
tion, and outcome data was developed from the input of 
physician representatives from the original nine hospi- 
tals. The data form went through several iterations be- 
fore a final “draft” was implemented for the pilot study 
(Table 1). A list of standard definitions using the Amer- 
ican College of Cardiology Guidelines as a reference 
was developed and sent to the sites with the data form. 
Definition of additional data elements not included in 
the American College of Cardiology database were 
agreed on by the participating centers. The data form 
was originally designed as a scannable form using 
Teleform technology (Cardiff Software Inc., Vista, 
CA, USA). More recently, dual manual data entry is 
used for transferring data into the database. 
Data Collection. Participating sites submitted the 
protocol to their respective Institutional Review 
Boards for approval prior to initiation. Because the 
project is a registry for quality assessment and quality 
improvement with no experimental interventions, and 
given that no direct patient identifiers are included in 
the database, informed consent was waived by the in- 
stitutions. Each site has a physician investigator and 
nurse coordinator for the study. The coordinators are 
required to keep an ongoing log of consecutive inter- 
ventional patients with instructions to complete one 
data form per procedure. (If one patient has two sepa- 
Table l. BMC2 Dataform: Four Iterations 
Version # I  6- 16-97 Final version used for pilot study 
based on experience from 
UMMC. 
study. (Practical tips to make 
form more user friendly.) 
lesion location, added new 
therapies (plavix, LMWHs). 
added new data elements (CPK 
prior, new devices, rescue 
reopro, other IIb/IIIa) 
27 in original; 17 in version #4 
15 in original; 23 in version #4 
Version #2 11-19-97 Incorporated feedback from pilot 
Version #3 5-22-98 Incorporated new ACC guide for 
Version #4 9-20-99 Changed to nonscannable form; 
Summary of variable changes: 
Comorbidities: 
Therapies: 
More details regarding lesions and devices in successive 
versions 
ACC = American College of Cardiology; BMC2 = Blue 
Cross Blue Shield of Michigan Cardiovascular Consortium; 
CPK = creatine phosphokinase; LMWH = low molecular 
weight heparin; UMMC = University of Michigan Medical 
Center. 
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rate interventions during the same hospitalization, two 
separate data forms are completed.) Each data form 
has a unique identifier (form number) that is linked to 
patient identifiers at each site for purposes of query 
resolution. The study coordinators have 2 months after 
the end of each quarter to complete data forms on con- 
secutive patients for that quarter. They send the data 
forms to the coordinating center where queries are re- 
solved before data are imported and quarterly reports 
are generated. 
Data Validation. All data goes through a three-step 
validation process before any reports are generated. 
The three steps include manual review for complete- 
ness and face validity, review of rejected data forms 
during the import process, and review of forms that fail 
diagnostic inquiries (Table 2). 
When data forms arrive at the coordinating center, 
they are first checked for completeness by the coordi- 
nating center staff. If a variable is omitted, a query is 
sent to the appropriate coordinator via e-mail asking 
for the missing variable. No data forms are scanned 
into the staging tables awaiting import into the 
database until all fields are complete. 
In addition, a random sample of data forms is 
checked for face validity. (All data forms from new 
sites and new coordinators are checked.) An example 
of review for face validity is checking for clinical con- 
sistency. For example, if nephropathy requiring dialy- 
sis is listed as an outcome, then an elevated creatinine 
level postprocedure would be expected. Similarly, if 
an intervention was performed within 24 hours of an 
acute myocardial infarction (MI), an elevated creati- 
nine phosphokinase level should be recorded in the 
labs section and Q-wave MI should not be marked in 
the outcomes section unless that particular patient de- 
veloped recurrent symptoms of an acute MI during the 
same hospitalization. 
Until June 2000, after resolution of the data form 
omissions, the data forms were scanned using Tele- 
form Software. Any questionable fields were high- 
lighted and reviewed before acceptance. More re- 
Table 2. BMC2 Data Process 
d 1. Face validity and completeness 5%* 
8-lo%* 
d 2. Import process 
d 3. Diagnostics 
(missing required fields, invalid data) 
(levels 1.2, and 3) 6%* 
*Percent of data forms queried. BMC2 = Blue Cross Blue 
Shield of Michigan Cardiovascular Consortium. 
cently, the Teleform phase has been eliminated and 
dual manual data entry is used. Dual manual data en- 
try is overall more reliable and, in the end, less time 
consuming. The data are then imported into staging ta- 
bles awaiting import into the Oracle database. Ap- 
proximately 8-10% of all data forms are rejected at 
this point due to preprogrammed constraints. Data 
forms will be rejected if required fields are missing or 
data are invalid (e.g., creatinine is recorded as 90). 
After resolution of these queries, the data are im- 
ported into an Oracle database where a series of diag- 
nostic reports are run to identify potential errors (Table 
3). All Level 1 and Level 2 diagnostics are resolved 
before quarterly reports are printed. 
Site Audits. All sites are audited twice yearly by a 
nurse practitioner from the coordinating center. (The 
coordinating center is audited by another BMC2 nurse 
coordinator.) During the site visit, a computerized 
printout of cases from each site is compared to the 
catheterization laboratory log to insure that all consec- 
utive interventional procedures have been captured. If 
cases are missing, the study coordinator is required to 
complete the data forms and send them to the coordi- 
Table 3. BMC’ Diagnostic Reports 
Once the data are imported onto Oracle, a series of diagnostic 
reports are run to identify potential errors. All Level 1 and 
Level 2 diagnostics are resolved before quarterly reports are 
printed. 
Level 1 
Invalid M.D. identifications 
Duplicate forms 
Age exceptions (< 30 or > 90) 
Procedure. date not within study period 
Procedure before admit date 
Procedure date before date of myocardial infarction (MI) 
Procedure date after discharge date 
Level 2 
Duplicate outcomes 
Low ejection fractions (< 10%) 
Admit date not within study 
Discharge date not within study 
MI date not within study 
Hospital stay > 90 days 
Hospital stay < 1 day 
Procedure > 30 days after MI 
Level 3 
Duplicate diabetic entries (IDDM vs NIDDM) 
Weight exceptions (> 300 or < 100) 
Weight missing 
MI present but no MI date 
Check for invalid MI dates 
By procedure data and date of birth 
By case number 
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nating center after the site visit. A random 2% sampling 
of cases is audited for accuracy. The variables on the 
original data form are compared to the hospital chart. In 
addition, all hard outcomes (any coronary artery bypass 
grafting [CABG], death) are audited for accuracy. 
7 
Results 
Participating Hospitals. Within the first 6 months, 
three of the nine original hospitals discontinued partic- 
ipation because they lacked resources to complete the 
data forms on consecutive interventional procedures. 
By the next calendar year, two of the original hospitals 
rejoined the registry resulting in a core group of eight 
hospitals (Fig. l), three academic and five community. 
These eight hospitals represent a diverse patient popu- 
lation served by community and academic hospitals in 
the state of Michigan. 
Data Form Evolution. Since the beginning of the 
registry, the BMC2 data form has gone through a total 
of four iterations. The second iteration incorporated 
feedback from the pilot study that included practical 
tips from the study coordinators to make the form 
more user friendly. Subsequent iterations have re- 
flected changing technology in interventional cardiol- 
ogy like the addition of new therapies and devices 
(Table 1). The data form also includes a “flex box” 
where short-term variables for ad hoc analysis may be 
added or deleted. More recently, the data entry process 
was changed from scannable forms to dual manual 
data entry to ensure further accuracy in the data entry 
and because the performance of the optical scanning 
system fell short of expectations. 
Data Validity. Approximately 5% of all data forms 
have at least one missing variable. The ten most fre- 
quently omitted variables are listed in Table 4. Base- 
line demographics like age and gender, and outcomes 
are important variables that are occasionally missing 
from the submitted data form. An additional 10% of 
forms are rejected at the import phase, and 6% are cur- 
rently rejected at the database level (Table 2). As 
shown in Figure 2 the overall number of queries has 
decreased by 30% since the pilot study. In the BMC2 
experience with centers that were added at a later 
stage, the number of omitted variables (and all queries) 
decreases as the coordinator becomes more experi- 
enced, representing a definite learning curve. As a re- 
sult of the data validity process, there is currently a 
100% completeness for mandatory fields such as age, 
gender, or outcomes prior to discharge. 
Missing cases are the most common problems iden- 
tified during the site visits. The number of missing 
cases ranges from 1 % to 18% of overall cases. Impor- 
tantly, the missing cases are usually emergency proce- 
dures performed during weekends or after hours, and 
are more likely to be associated with adverse out- 
comes. 
Quarterly Reports. Once the data are clean and 
complete, quarterly reports are printed for each site. 
These reports include a column that lists the collabo- 
rative data, a column for site data, and a third column 
with individual physician data. All sites and physi- 
cians are coded by number and only the individual site 
study coordinator has physician and patient identifiers. 
This allows individual practitioners and sites to com- 
pare their practices/outcomes with the collaborative. 
The quarterly reports include nine separate pages de- 
tailing demographics, case mix, preprocedure therapy, 
procedure data by patient, procedure data by lesion, 
outcomes in the laboratory, outcomes prior to dis- 
charge, and mortality. The mortality data are shown as 
observed and 
Table 4. Ten Most Frequently Queried Variables 
Category Post procedure stenosis 
ACC lesion type Gender 
Number grafts > 70% MI date 
Device LM disease 
DOB Outcomes prior to D/C 
Figure 1. Number of participating hospital over time and study 
phases. 
ACC = American College of Cardiology; D/C = discharge; 
DOB = date of birth; LM = left main; MI = myocardial in- 
farction. 
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Figure 2. Average percentage and range of forms requiring query 
resolution at the beginning of the study and more recently. 
Discussion 
The BMC2 is one of several multicenter interven- 
tional registries within the United States designed to 
document procedural data and clinical outcomes in pa- 
tients undergoing PCIs. The National Heart, Lung, and 
Blood Institute Percutaneous Transluminal Coronary 
Angioplasty (PTCA) Registries provided information 
on consecutive cases during two distinct time periods 
(1979 through 1981 and 1985 through 1986)4 from 16 
participating North American hospitals, and has pro- 
vided extensive data on outcomes of conventional per- 
cutaneous balloon angioplasty. More recently, the 
New Approaches to Coronary Intervention (NACI) 
Registry was developed to collect in-depth data about 
patients being treated with new interventional tech- 
n i q u e ~ ~  with an emphasis on stringent procedural data 
collection. Other examples of large registries at na- 
tional and state levels include the National Cardiovas- 
cular Network Database (NCN), the American College 
of Cardiology National Data registry, the State of Cal- 
ifornia Hospital discharge abstract data, and the state 
of New York Coronary Angioplasty Reporting Sys- 
tem. So far, the State of California registry and the 
New York State registries have reported outcomes 
from data collected in 1989 and 1991 (New Y ~ r k ) . ~ , ~  
The NCN is a multicenter outcome-based organization 
established to foster interventional contracts with 
health care purchasers and to document clinical data 
and stimulate quality improvement.' On a regional 
level, The Northern New England Cardiovascular Dis- 
ease Study Group (NNECVDSG) is an ongoing vol- 
untary consortium that has been collecting data on per- 
cutaneous revascularization procedures since 1990.' 
BMC2 is a consortium similar to the NNECVDSG, 
and it represents an example of a spontaneous collab- 
orative effort at a regional level. Thus, since the initial 
introduction of PTCA in 1977, several registries have 
been collecting data on PCIs on a regional or national 
level to better understand clinical outcomes. 
The data from the present registry show that out- 
come assessment does not end with the creation of a 
single center or a multicenter registry, but requires the 
institution of a process aimed toward the assurance of 
the quality of the data entered in the database, which is 
necessary to assure analytic rigor and credibility. Such 
assurance includes ascertainment of submission of 
consecutive cases, and of data completeness, particu- 
larly in relation to key fields like baseline demograph- 
ics and major postprocedural outcomes. In addition, 
clinical inconsistencies and out of range data are other 
common problems in the data collection process that 
can be easily resolved with automatic internal queries 
and reports. Database efforts that fail to undertake this 
level of data scrutiny will be significantly weakened 
by essential data that are missing or inaccurate. 
The process instituted in the present system includes 
review of charts of procedures where a major adverse 
outcome was reported, and an additional 2% random 
chart review. Obviously, review of every chart might 
further assure data quality. However, this effort would 
have insurmountable budgetary constraints for a vol- 
untary consortium with limited funding like BMC2. 
However, no chart review at all could open the possi- 
bility of inaccurate or incomplete data collection, and 
of gaming. Thus, the authors believe that chart review 
limited to procedures where a major adverse outcome 
was reported and to an additional 2% of charts ran- 
domly selected is a reasonable compromise that can 
help in assuring the accuracy of the data collection 
process and in limiting gaming. They have found that 
these audits identify patterns of inaccuracy at a given 
institution that can be rectified through dialogue with 
the study coordinator. In addition, the comparison of 
the database logs with the procedures logs in the par- 
ticipating institutions appears to be the only way to as- 
sure the inclusion of consecutive cases. 
Finally, the authors believe that the success of the 
BMC2 data collection effort reflects not only the pro- 
cess described here, but also the collaborative and vol- 
untary nature of the consortium, the development of a 
common data form with a standard set of definitions, 
and the presence of dedicated clinical coordinators at 
each participating site. 
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Conclusion 
The BMC2 was designed to provide interventional 
cardiology practitioners with timely, valid information 
regarding current interventional practices and out- 
comes along with benchmarking data to use for qual- 
ity improvement purposes. Analysis of the data so far 
collected and a quality improvement effort are cur- 
rently underway. 
Appendix 
BMC2 Hospitals and Working Group Members. 
University of Michigan Health System in Ann Arbor 
(BMC2 Coordinating Center): Kim A. Eagle, M.D., 
F.A.C.C., Mauro Moscucci, M.D., Eva Kline-Rogers, 
M.S., R.N., Diane Bondie, B.S., Bruce Rogers, B.S., 
Jeanna Cooper, M.S.; Blue Cross Blue Shield of Michi- 
gan: David Share, M.D.; Northern Michigan Hospitals 
in Petoskey: William Meengs, M.D., Robert Sloan, 
M.B.A., Cindy Bodurka, R.N.; Spectrum Health 
Downtown in Grand Rapids: William McNamara, 
M.D., Ann M. Eward, Ph.D., Sherri Kanten, R.N., Re- 
nee Stamper, J.D.; McLaren Regional Medical Center 
in Flint: Anthony DeFranco, M.D., F.A.C.C., James 
Chambers, D.O., Cathy Fisk, R.N., L i s a  Pertler, R.N., 
Stacey Somsky, R.N.; St. Joseph Mercy Hospital in 
Ann Arbor: Michael O’Donnell, M.D., Patricia Wren, 
R.N.; St. Joseph Mercy Hospital in Pontiac: Kirit Pa- 
tel, M.D., Susan Wright, R.N., Bethany Smith, R.N.; 
Harper Hospital in Detroit: John McGinnity, M.S., 
P.A.-C., Cathy June, R.N.; Henry Ford Hospital in 
Detroit: Vivian Clark, M.D., Phillip Kraft, M.D., Lau- 
rel Dvorak, R.N., Kelly Ryan, R.N., Margaret Fox, 
R.N., Cathy Lucarelli, R.N. 
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